Physician profile
Audra W Eason
NPI 1174788970
$4,811.91
in general payments reported to CMS, 2019-2025
44 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,070 · 2020: $333 · 2021: $566 · 2022: $434 · 2023: $598 · 2024: $916 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,409.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,409.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,145.62 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Merz North America, INC. | $349.97 | 2024-2025 | |
| Nevro Corp. | $348.28 | 2019-2023 | Senza |
| Scilex Pharmaceuticals INC. | $291.67 | 2019-2024 | Ztlido |
| Amgen INC. | $221.29 | 2019-2022 | |
| Zyla Life Sciences, INC. | $189.34 | 2019-2020 | |
| Medtronic, INC. | $183.90 | 2024 | Intellis Adaptivestim |
| Pfizer INC. | $182.23 | 2019-2023 | |
| Revance Therapeutics, INC. | $177.06 | 2025 | Daxxify |
| Galderma Laboratories, L.P. | $164.60 | 2025 | |
| Mdd US Operations, LLC | $151.65 | 2019 | |
| Collegium Pharmaceutical, INC. | $145.08 | 2019-2024 | Xtampza |
| Abbott Laboratories | $138.13 | 2019-2023 | Proclaim |
| Allergan, INC. | $114.10 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $89.44 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Eason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.